AKELOS, INC.

Is this your business?

Get access!

Company Details

Name:

AKELOS, INC.

Jurisdiction:

New York

Legal type:

FOREIGN DESIGNATION OF THE SECRETARY OF STATE

Status:

Recorded

Date of registration:

06 Dec 2018 (7 years ago)

Date of dissolution:

06 Dec 2018

Entity Number:

5454668

County:

Blank

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:

www.akelosinc.com

Phone Number:

917-747-2006

E-mail Address:

drstevefox@aol.com

Contact Person:

STEVEN FOX

Ownership and Self-Certifications:

Self-Certified Small Disadvantaged Business

User ID:

P2396969

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:

JLTKFBSDPLR4

CAGE Code:

8CL63

UEI Expiration Date:

2026-04-25

Business Information

URL:

www.akelosinc.com

Activation Date:

2025-04-29

Initial Registration Date:

2019-07-22

USAspending Awards / Financial Assistance

Date:

2022-09-25

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

OPTIMIZATION OF AN HCN1-SELECTIVE INVERSE AGONIST FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN - PROJECT SUMMARY/ABSTRACT IN THE UNITED STATES, AT LEAST 116 MILLION ADULTS SUFFER FROM CHRONIC PAIN; THE ASSOCIATED COSTS EXCEED $500 BILLION/YR. NEUROPATHIC PAIN (CHRONIC PAIN ASSOCIATED WITH ABERRANT ACTIVITY IN THE CENTRAL AND/OR PERIPHERAL NERVOUS SYSTEM) ACCOUNTS FOR 18% OF PATIENTS WITH CHRONIC PAIN. OPIOID ANALGESICS ARE ROUTINELY PRESCRIBED FOR THE TREATMENT OF CHRONIC PAIN BUT THERE ARE SUBSTANTIAL RISKS INVOLVED WITH SUCH THERAPY, INCLUDING PHYSICAL DEPENDENCE, ADDICTION, AND FATAL POISONING. THE GOALS OF THIS PROJECT ARE TO OPTIMIZE THE ACTIVE PHARMACOPHORE COMPONENT OF OUR IDENTIFIED LEAD COMPOUND AND USE THAT NOVEL MOLECULE TO CREATE A POTENT, NON-OPIOID THERAPEUTIC FOR THE TREATMENT OF PERIPHERAL SENSORY NEUROPATHIC PAIN. IH CURRENT-DRIVEN HYPEREXCITABILITY IN SENSORY NEURONS CONTRIBUTES TO NEUROPATHIC PAIN. WE HAVE PREVIOUSLY DEMONSTRATED THAT THE WIDELY USED AND SAFE GENERAL ANESTHETIC PROPOFOL (2,6-DI-ISO-PROPYLPHENOL), AS WELL AS CLOSELY RELATED ANALOGUES, ARE POTENT HCN1 INVERSE AGONISTS (I.E., THEY ACT AS INHIBITORS OF CHANNEL FUNCTION), MARKEDLY SPARING OTHER HCN ISOFORMS INCLUDING THOSE THAT FORM CARDIAC IH (HCN4 AND 2). IMPORTANTLY, SUB- HYPNOTIC PROPOFOL AND THE NON-ANESTHETIC 2,6-DI-TERT-BUTYLPHENOL (2,6-DTBP) SUPPRESS NEUROPATHIC HYPERALGESIA WHILE LARGELY SPARING NORMAL NOCICEPTION. HERE WE WILL SCREEN IN VITRO A COMPOUND LIBRARY CONSTRAINED BY KNOWN INVERSE AGONIST-SITE CHARACTERISTICS OF ALKYLPHENOL CONGENERS TO IDENTIFY NOVEL POTENT, SELECTIVE HCN1 CHANNEL INVERSE AGONISTS; USE IN SILICO MODELING TO PREDICT AND THEN SYNTHESIZE ADDITIONAL NOVEL, POTENT, HCN1-SELECTIVE MOLECULES; AND CONDUCT IN VIVO STUDIES USING THE TWO MOST POTENT OF THOSE NOVEL COMPOUNDS TO ASSESS ANTI-HYPERALGESIC EFFICACY AND SAFETY. SUCCESSFUL COMPLETION OF THE PROPOSED WORK WILL CREATE AN URGENTLY NEEDED, HIGHLY-EFFECTIVE, NON-OPIOID, TREATMENT FOR NEUROPATHIC PAIN.

Obligated Amount:

698818.00

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Trademarks Section

Serial Number:

88170591

Mark:

AKELOS

Status:

SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED

Mark Type:

SERVICE MARK

Application Filing Date:

2018-10-26

Mark Drawing Type:

Standard character mark

Mark Literal Elements:

AKELOS

USPTO Link:

View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:

Medical research namely, clinical trial services; Pharmaceutical research and development services; biological research; chemical research; Testing of pharmaceuticals; Pharmaceutical drug development services; Laboratory research services relating to pharmaceuticals; Providing medical and scientific...

First Use:

2018-11-01

International Classes:

042 - Primary Class

Class Status:

Active

AKELOS, INC.

Is this your business?

Company Details

U.S. Small Business Administration Profile

Unique Entity ID

Business Information

USAspending Awards / Financial Assistance

Trademarks Section

Goods And Services

Reviews Leave a review

Related by officers

Related by address